I
Ingrid A. Boere
Researcher at Erasmus University Rotterdam
Publications - 26
Citations - 878
Ingrid A. Boere is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Pregnancy & Cancer. The author has an hindex of 13, co-authored 26 publications receiving 660 citations.
Papers
More filters
Journal ArticleDOI
Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy
Frédéric Amant,Tineke Vandenbroucke,Magali Verheecke,Monica Fumagalli,Michael J. Halaska,Ingrid A. Boere,Sileny Han,Mina Mhallem Gziri,Fedro A. Peccatori,Lukas Rob,Christianne A. R. Lok,Petronella O. Witteveen,Jens-Uwe Voigt,Gunnar Naulaers,Lore Vallaeys,Frank Van den Heuvel,Lieven Lagae,Luc Mertens,Laurence Claes,Kristel Van Calsteren +19 more
TL;DR: Prenatal exposure to maternal cancer with or without treatment did not impair the cognitive, cardiac, or general development of children in early childhood andPrematurity was correlated with a worse cognitive outcome, but this effect was independent of cancer treatment.
Journal ArticleDOI
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer.
Bo Gao,Bo Gao,Yi Lu,Annemieke J.M. Nieuweboer,Hongmei Xu,Jonathan Beesley,Ingrid A. Boere,Anne Joy M. de Graan,Peter de Bruijn,Howard Gurney,Catherine J. Kennedy,Catherine J. Kennedy,Yoke Eng Chiew,Yoke Eng Chiew,Sharon E. Johnatty,Philip Beale,Michelle Harrison,Craig Luccarini,Don M. Conroy,Ron H.J. Mathijssen,Paul R. Harnett,Paul R. Harnett,Rosemary L. Balleine,Georgia Chenevix-Trench,Stuart MacGregor,Anna de Fazio +25 more
TL;DR: It is found that carboplatin and paclitaxel disposition are stable phenotypes in ovarian cancer patients and genome-wide association study (GWAS) of chemotherapeutic drug disposition can be effective, even in relatively small cohorts, and can be adopted in drug development and treatment programs.
Journal ArticleDOI
Monitoring In Situ Dosimetry and Protoporphyrin IX Fluorescence Photobleaching in the Normal Rat Esophagus During 5-Aminolevulinic Acid Photodynamic Therapy {
Ingrid A. Boere,Dominic J. Robinson,H.S. de Bruijn,J. van den Boogert,Hugo W. Tilanus,Henricus J. C. M. Sterenborg,R.W.F. de Bruin +6 more
TL;DR: In situ light dosimetry was used to adjust the fluence rate measured within the esophagus for individual animals and monitored protoporphyrin IX (PpIX) fluorescence photobleaching simultaneously, and it was found that higher PpIX fluorescence photography rates corresponded with more epithelial damage, whereas lower rates corresponding with no response.
Journal ArticleDOI
Use of fibre optic probes for detection of Barrett’s epithelium in the rat oesophagus by Raman spectroscopy
TL;DR: A multivariate classification model was developed for detection of Barrett's epithelium, based on ex vivo Raman spectra of the rat oesophagus, and this model yields a spectral discriminant that best separates the two groups.
Journal ArticleDOI
Protoporphyrin IX fluorescence photobleaching and the response of rat Barrett's esophagus following 5-aminolevulinic acid photodynamic therapy
Ingrid A. Boere,Dominic J. Robinson,Henriëtte S. de Bruijn,Jolanda Kluin,Hugo W. Tilanus,Henricus J. C. M. Sterenborg,Ron W. F. de Bruin +6 more
TL;DR: In vivo dosimetry is feasible in heterogeneous conditions such as BE, and PpIX fluorescence photobleaching is useful to predict the tissue response to ALA-PDT, as observed in a rat model of BE.